6:31 PM
Dec 12, 2014
 |  BC Extra  |  Top Story

ChemoCentryx rebounds on updated diabetic nephropathy data

ChemoCentryx Inc. (NASDAQ:CCXI) jumped $1.11 (25%) to $5.60 on Friday after reporting that CCX140 plus standard of care met the primary endpoint of reducing the urine albumin-to-creatinine ratio (UACR) over 52 weeks vs. placebo plus SOC in a Phase II trial to treat diabetic nephropathy. SOC consisted of stable doses of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB).


Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >